Discover how the latest breakthroughs in folate receptor alpha (FRα)-targeted antibody-drug conjugates (ADCs) are redefining what’s possible with biomarker-driven therapy! From landmark clinical findings to promising next-generation ADCs, new treatment opportunities are expanding care across the…
The frontline management of chronic lymphocytic leukemia (CLL) has never offered more promise or demanded greater clinical precision. Biomarker-guided treatment selection and an expanding arsenal of targeted therapies are redefining standards of care. However, clinicians continue…
Relapsed/refractory multiple myeloma (RRMM) remains clinically heterogeneous and increasingly difficult to control across successive lines of therapy, particularly among patients with high-risk disease, extramedullary involvement, or cumulative immune compromise. B-cell maturation antigen (BCMA)-targeted bispecific antibodies have…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Discover how the latest breakthroughs in folate receptor alpha (FRα)-targeted antibody-drug conjugates (ADCs) are redefining what’s possible with biomarker-driven therapy! From landmark clinical findings to promising next-generation ADCs, new treatment opportunities are expanding care across the…
Muscle-invasive bladder cancer (MIBC) remains one of the most aggressive urologic cancers, with poor long-term outcomes driven by limited systemic therapy options and frequent micrometastatic disease at diagnosis. Immune checkpoint inhibitors (ICIs) are transforming the treatment…
Neurofibromatosis type 1 (NF1) is a rare, complex, and often under-recognized condition that presents significant diagnostic and management challenges, particularly for oncology nurses who play a central role in longitudinal patient care. Despite recent advances, including…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Management of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PNs) has evolved rapidly and now includes indications across age groups. NF1 remains a complex, lifelong condition with diverse and evolving manifestations, requiring clinicians to maintain up-to-date knowledge of…
Despite significant advances in the management of advanced or recurrent endometrial cancer (EC)—including the use of molecular classification, immune checkpoint inhibitors, and targeted therapies—delivering timely, guideline-compliant care remains complex. Rapidly evolving clinical evidence, the growing role…
